Amgen Inc (AMGN)
262.71
-1.33
(-0.50%)
USD |
NASDAQ |
Apr 18, 16:00
262.75
+0.04
(+0.02%)
After-Hours: 20:00
Amgen Cash from Financing (Quarterly): 2.754B for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.754B |
| September 30, 2023 | -2.005B |
| June 30, 2023 | -1.21B |
| March 31, 2023 | 21.51B |
| December 31, 2022 | -1.049B |
| September 30, 2022 | 1.588B |
| June 30, 2022 | -1.062B |
| March 31, 2022 | -3.514B |
| December 31, 2021 | -6.558B |
| September 30, 2021 | 2.848B |
| June 30, 2021 | -2.622B |
| March 31, 2021 | -1.939B |
| December 31, 2020 | -3.59B |
| September 30, 2020 | -1.798B |
| June 30, 2020 | 775.00M |
| March 31, 2020 | -254.00M |
| December 31, 2019 | -1.929B |
| September 30, 2019 | -2.859B |
| June 30, 2019 | -5.992B |
| March 31, 2019 | -4.987B |
| December 31, 2018 | -3.568B |
| September 30, 2018 | -2.58B |
| June 30, 2018 | -4.65B |
| March 31, 2018 | -11.69B |
| December 31, 2017 | -2.134B |
| Date | Value |
|---|---|
| September 30, 2017 | -1.107B |
| June 30, 2017 | -1.242B |
| March 31, 2017 | -2.111B |
| December 31, 2016 | -2.122B |
| September 30, 2016 | 582.00M |
| June 30, 2016 | -2.286B |
| March 31, 2016 | 1.227B |
| December 31, 2015 | -922.00M |
| September 30, 2015 | -1.458B |
| June 30, 2015 | 6.00M |
| March 31, 2015 | -1.397B |
| December 31, 2014 | -3.162B |
| September 30, 2014 | -513.00M |
| June 30, 2014 | 896.00M |
| March 31, 2014 | -495.00M |
| December 31, 2013 | 3.807B |
| September 30, 2013 | 2.787B |
| June 30, 2013 | -283.00M |
| March 31, 2013 | -3.585B |
| December 31, 2012 | -1.347B |
| September 30, 2012 | 1.424B |
| June 30, 2012 | 1.707B |
| March 31, 2012 | -1.365B |
| December 31, 2011 | 1.691B |
| September 30, 2011 | -2.219B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.558B
Minimum
Dec 2021
21.51B
Maximum
Mar 2023
-363.53M
Average
-1.798B
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Gilead Sciences Inc | -1.099B |
| Johnson & Johnson | -4.655B |
| Eli Lilly and Co | 3.545B |
| Merck & Co Inc | -2.245B |
| Vertex Pharmaceuticals Inc | -119.80M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 538.00M |
| Cash from Investing (Quarterly) | -27.09B |
| Free Cash Flow | 7.359B |
| Free Cash Flow Per Share (Quarterly) | 0.5372 |
| Free Cash Flow to Equity (Quarterly) | -3.856B |
| Free Cash Flow to Firm (Quarterly) | 1.028B |
| Free Cash Flow Yield | 5.21% |